Valneva Dirección

Dirección controles de criterios 1/4

El CEO de Valneva es Thomas Lingelbach , nombrado en May 2013, tiene una permanencia de 11.5 años. compensación anual total es €919.56K, compuesta por 58.8% salario y 41.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.24% de las acciones de la empresa, por valor de €729.45K. La antigüedad media del equipo directivo y de la junta directiva es de 0.9 años y 1.7 años, respectivamente.

Información clave

Thomas Lingelbach

Chief Executive Officer (CEO)

€919.6k

Compensación total

Porcentaje del salario del CEO	58.8%
Permanencia del CEO	11.5yrs
Participación del CEO	0.2%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	1.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thomas Lingelbach en comparación con los beneficios de Valneva?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-€7m
Jun 30 2024	n/a	n/a	-€32m
Mar 31 2024	n/a	n/a	-€24m
Dec 31 2023	€920k	€541k	-€101m
Sep 30 2023	n/a	n/a	-€113m
Jun 30 2023	n/a	n/a	-€7m
Mar 31 2023	n/a	n/a	-€135m
Dec 31 2022	€784k	€525k	-€143m
Sep 30 2022	n/a	n/a	€73m
Jun 30 2022	n/a	n/a	-€159m
Mar 31 2022	n/a	n/a	-€72m
Dec 31 2021	€769k	€420k	-€73m
Sep 30 2021	n/a	n/a	-€248m
Jun 30 2021	n/a	n/a	-€125m
Mar 31 2021	n/a	n/a	-€91m
Dec 31 2020	€649k	€376k	-€64m
Sep 30 2020	n/a	n/a	-€62m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€8m
Dec 31 2019	€1m	€384k	-€2m
Sep 30 2019	n/a	n/a	€4m
Jun 30 2019	n/a	n/a	€1m
Mar 31 2019	n/a	n/a	€7m
Dec 31 2018	€694k	€377k	€3m
Sep 30 2018	n/a	n/a	-€7m
Jun 30 2018	n/a	n/a	-€7m
Mar 31 2018	n/a	n/a	-€8m
Dec 31 2017	€649k	€367k	-€11m

Compensación vs. Mercado: La compensación total ($USD963.90K) de Thomas está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD1.03M).

Compensación vs. Ingresos: La compensación de Thomas ha aumentado mientras la empresa no es rentable.

CEO

Thomas Lingelbach (61 yo)

11.5yrs

Permanencia

€919,563

Compensación

Mr. Thomas Lingelbach has been the Chief Executive Officer of Valneva SE since May 2013 and served as its Chairman and Member of the Management Board since May 10, 2013 until December 20, 2023 and serves a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Lingelbach	President	11.5yrs	€919.56k	0.24% € 729.5k
Peter Buhler	Chief Financial Officer	no data	€558.83k	0.028% € 84.7k
Franck Grimaud	Chief Business Officer	less than a year	€401.34k	0.39% € 1.2m
Juan-Carlos Jaramillo	Chief Medical Officer	less than a year	€539.76k	0.028% € 84.7k
Dipal Patel	Chief Commercial Officer	less than a year	€516.75k	sin datos
Vincent Dequenne	Chief Operating Officer	no data	sin datos	sin datos
Hanneke Schuitemaker	Chief Scientific Officer	less than a year	sin datos	sin datos
Joshua Drumm	Vice President of Investor Relations	3.3yrs	sin datos	sin datos
Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations	no data	sin datos	sin datos
Petra Pesendorfer	Chief People Officer	less than a year	sin datos	sin datos
Christian Taucher	Head of Global Medical Affairs	no data	sin datos	sin datos
Susanne Eder-Lingelbach	Head of Clinical Operations	no data	sin datos	sin datos

0.9yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AYJ no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Lingelbach	President	less than a year	€919.56k	0.24% € 729.5k
James Sulat	Director	less than a year	€74.07k	0.019% € 57.4k
Alexander Von Gabain	Member of Scientific Advisory Board	4.8yrs	€10.00k	sin datos
James Connolly	Director	less than a year	€66.11k	sin datos
Kathrin Jansen	Director	less than a year	€28.25k	sin datos
Mailys Ferrere	Director	less than a year	sin datos	sin datos
George R. Siber	Member of Scientific Advisory Board	5yrs	sin datos	sin datos
Ralf Leo Clemens	Chair of Scientific Advisory Board	5.3yrs	€2.92k	sin datos
Norman Baylor	Member of Scientific Advisory Board	5yrs	sin datos	sin datos
Anne-Marie Graffin	Chairman	less than a year	€74.30k	0.0088% € 27.0k
Thomas Decker	Member of Scientific Advisory Board	2.5yrs	sin datos	sin datos
Michael Pfleiderer	Member of Scientific Advisory Board	2.5yrs	sin datos	sin datos

1.7yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de AYJ no se considera experimentada (1.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Valneva Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE Announces Board Changes

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Recent updates

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Forecast to breakeven in 2024

Third quarter 2024 earnings released: €0.066 loss per share (vs €0.25 loss in 3Q 2023)

New minor risk - Financial position

Valneva SE to Report Nine Months, 2025 Results on Nov 13, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

New minor risk - Shareholder dilution

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Second quarter 2024 earnings released: €0.19 loss per share (vs €0.12 loss in 2Q 2023)

No longer forecast to breakeven

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

First quarter 2024 earnings released: EPS: €0.42 (vs €0.13 loss in 1Q 2023)

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Full year 2023 earnings released: €0.73 loss per share (vs €1.24 loss in FY 2022)

New minor risk - Profitability

Now 20% undervalued after recent price drop

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Forecast to breakeven in 2024

Valneva Se Announces Earnings Guidance for 2024

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

No longer forecast to breakeven

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Third quarter 2023 earnings released: €0.25 loss per share (vs €0.68 profit in 3Q 2022)

New minor risk - Share price stability

Valneva Se Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: €0.12 loss per share (vs €1.34 loss in 2Q 2022)

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

New minor risk - Financial position

Valneva SE announced a financing transaction

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Forecast breakeven date moved forward to 2023

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE Provides Financial Guidance of 2023

First quarter 2023 earnings released: €0.13 loss per share (vs €0.24 loss in 1Q 2022)

No longer forecast to breakeven

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report First Half, 2023 Results on Aug 10, 2023

Valneva SE Reports Further Heterologous Booster Data from Exploratory, Small Clinical Study for its Inactivated COVID-19 Vaccine, VLA2001

Valneva Completes BLA Submission to U.S. FDA for Its Single-Shot Chikungunya Vaccine Candidate

Valneva SE to Report Q1, 2023 Results on May 04, 2023

Investor sentiment improved over the past week

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

ValnevaSE Appoints Dipal Patel as Chief Commercial Officer

Valneva SE Reiterates Earnings Guidance for the Fiscal 2022

Valneva to Present on Its Single-Shot Chikungunya Vaccine Candidate At Leading Scientific Conferences

Valneva SE announced a financing transaction

No longer forecast to breakeven

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Valneva SE Confirms World Health Organization Recommendations for its Inactivated COVID-19 Vaccine

Valneva SE Initiates Rolling Submission of U.S. Food and Drug Administration Biologics License Application for Its Single Shot Chikungunya Vaccine Candidate

Second quarter 2022 earnings released: €1.34 loss per share (vs €0.60 loss in 2Q 2021)

Valneva SE Provides Revenue Guidance for the Fiscal Year 2022

Pfizer Inc. and Valneva SE Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Forecast breakeven date pushed back to 2024

Valneva Announces Initiation of the Phase 3 Study of Lyme Disease Vaccine

Análisis de compensación del CEO

CEO